Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials

Thrombosis Research

Volumn 144, Issue , 2016, Pages 32-39

  Elbers, Laura P B ^a,b   Sjouke, Barbara ^a   Zannad, Faïez ^c,d,e   Cicoira, Mariantonietta ^f   Vizzardi, Enrico ^g   Václavík, Jan ^h   Gerdes, Victor E A ^a,b   Squizzato, Alessandro ⁱ  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c INSERM UMR S 1116 University of Lorraine   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f UNIVERSITY OF VERONA   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

ⁱ UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Aldosterone; Bleeding; Mineralocorticoid receptor antagonists; Thrombosis

Indexed keywords

CANRENOIC ACID; CANRENONE; EPLERENONE; FINERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; ALDOSTERONE;

ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG SAFETY; EMBASE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; HEMOSTASIS; HYPERALDOSTERONISM; METABOLISM; MORTALITY; RISK; THROMBOSIS;

ALDOSTERONE; CARDIOVASCULAR DISEASES; HEMORRHAGE; HEMOSTASIS; HUMANS; HYPERALDOSTERONISM; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; THROMBOSIS;

EID: 84971614239     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.04.027     Document Type: Review

References (37)

1. N.J. Brown Eplerenone: cardiovascular protection Circulation 107 2003 2512 2518
2. A.D. Struthers, and T.M. MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc. Res. 61 2004 663 670
3. A. Gromotowicz, J. Szemraj, A. Stankiewicz, A. Zakrzeska, M. Mantur, E. Jaroszewicz, F. Rogowski, and E. Chabielska Study of the mechanisms of aldosterone prothrombotic effect in rats J. Renin-Angiotensin-Aldosterone Syst. 12 2011 430 439
4. A. Stankiewicz, A. Gromotowicz, J. Szemraj, M. Wojewodzka-Zelezniakowicz, P. Skrzypkowski, and E. Chabielska Acute aldosterone infusion enhances thrombosis development in normotensive rats Thromb. Haemost. 98 2007 697 699
5. N.J. Brown, D.E. Vaughan, and A.B. Fogo Aldosterone and PAI-1: implications for renal injury J. Nephrol. 15 2002 230 235
6. P. Sawathiparnich, S. Kumar, D.E. Vaughan, and N.J. Brown Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans J. Clin. Endocrinol. Metab. 87 2002 448 452
7. J. Ma, F. Albornoz, C. Yu, D.W. Byrne, D.E. Vaughan, and N.J. Brown Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance Hypertension 46 2005 313 320
8. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, and J.J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J. Am. Coll. Cardiol. 45 2005 1243 1248
9. K. Verhamme, G. Mosis, J. Dieleman, B. Stricker, and M. Sturkenboom Spironolactone and risk of upper gastrointestinal events: population based case-control study BMJ 333 2006 330
10. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med. 6 2009 e1000097
11. S. Schulman, C. Kearon, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J. Thromb. Haemost. 3 2005 692 694
12. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, Cochrane Bias Methods G, and Cochrane Statistical Methods G The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
13. S. Tandon, N. Munir, N.J. Roland, J. Lancaster, S.R. Jackson, and T.M. Jones A systematic review and number needed to treat analysis to guide the management of the neck in patients with squamous cell carcinoma of the head and neck Auris Nasus Larynx 38 2011 702 709
14. M. Akbulut, Y. Ozbay, E. Ilkay, I. Karaca, and N. Arslan Effects of spironolactone and metoprolol on QT dispersion in heart failure Jpn. Heart J. 44 2003 681 692
15. A. Boccanelli, G.F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, A.P. Maggioni, S. Masson, M. Vanasia, G. de Simone, and A.I.-C. Investigators Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results Eur. J. Heart Fail. 11 2009 68 76
16. L. Bolondi, F. Piscaglia, A. Gatta, F. Salerno, M. Bernardi, A. Ascione, O. Ferrau, D. Sacerdoti, S. Visentin, F. Trevisani, R. Mazzanti, G. Donati, U. Arena, P. Gentilini, and D.O.C.S. Group Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis Clin. Gastroenterol. Hepatol. 4 2006 1395 1402
17. D.A. Calhoun, W.B. White, H. Krum, W. Guo, G. Bermann, A. Trapani, M.P. Lefkowitz, and J. Menard Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial Circulation 124 2011 1945 1955
18. M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Brighetti, P. Marino, and P. Zardini Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure J. Am. Coll. Cardiol. 40 2002 304 310
19. A. Deswal, P. Richardson, B. Bozkurt, and D.L. Mann Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF) J. Card. Fail. 17 2011 634 642
20. F. Edelmann, R. Wachter, A.G. Schmidt, E. Kraigher-Krainer, C. Colantonio, W. Kamke, A. Duvinage, R. Stahrenberg, K. Durstewitz, M. Loffler, H.D. Dungen, C. Tschope, C. Herrmann-Lingen, M. Halle, G. Hasenfuss, G. Gelbrich, B. Pieske, and D.H.F.I. Aldo Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial JAMA 309 2013 781 791
21. H. Krum, H. Nolly, D. Workman, W. He, B. Roniker, S. Krause, and K. Fakouhi Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients Hypertension 40 2002 117 123
22. C.S. Oxlund, J.E. Henriksen, L. Tarnow, K. Schousboe, J. Gram, and I.A. Jacobsen Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial J. Hypertens. 31 2013 2094 2102
23. B. Pitt, L. Kober, P. Ponikowski, M. Gheorghiade, G. Filippatos, H. Krum, C. Nowack, P. Kolkhof, S.Y. Kim, and F. Zannad Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial Eur. Heart J. 34 2013 2453 2463
24. B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, N. Clausell, A.S. Desai, R. Diaz, J.L. Fleg, I. Gordeev, B. Harty, J.F. Heitner, C.T. Kenwood, E.F. Lewis, E. O'Meara, J.L. Probstfield, T. Shaburishvili, S.J. Shah, S.D. Solomon, N.K. Sweitzer, S. Yang, S.M. McKinlay, and T. Investigators Spironolactone for heart failure with preserved ejection fraction N. Engl. J. Med. 370 2014 1383 1392
25. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin, E. Eplerenone Post-Acute Myocardial Infarction Heart Failure, and I. Survival Study Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321
26. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators N. Engl. J. Med. 341 1999 709 717
27. S. Taheri, M. Mortazavi, A. Pourmoghadas, S. Seyrafian, Z. Alipour, and S. Karimi A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis Saudi J. Kidney Dis. Transpl. 23 2012 507 512
28. J. Vaclavik, R. Sedlak, M. Plachy, K. Navratil, J. Plasek, J. Jarkovsky, T. Vaclavik, R. Husar, E. Kocianova, and M. Taborsky Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial Hypertension 57 2011 1069 1075
29. E. Vizzardi, A. D'Aloia, R. Giubbini, T. Bordonali, S. Bugatti, N. Pezzali, A. Romeo, A. Dei Cas, M. Metra, and C.L. Dei Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure Am. J. Cardiol. 106 2010 1292 1296
30. E. Vizzardi, S. Nodari, G. Caretta, A. D'Aloia, N. Pezzali, G. Faden, C. Lombardi, R. Raddino, M. Metra, and C.L. Dei Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms Am. J. Med. Sci. 347 2014 271 276
31. W.B. White, A.A. Carr, S. Krause, R. Jordan, B. Roniker, and W. Oigman Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension Am. J. Cardiol. 92 2003 38 42
32. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, B. Pitt, and E.-H.S. Group Eplerenone in patients with systolic heart failure and mild symptoms N. Engl. J. Med. 364 2011 11 21
33. D.J. Stuijver, E. Romualdi, B. van Zaane, L. Bax, H.R. Buller, V.E. Gerdes, and A. Squizzato Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis Intern. Emerg. Med. 10 2015 219 246
34. J.A. Ezekowitz, and F.A. McAlister Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials Eur. Heart J. 30 2009 469 477
35. T. Walter, S. Szabo, S. Kazmaier, T. Suselbeck, M. Borggrefe, and H.M. Hoffmeister Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting Thorac. Cardiovasc. Surg. 57 2009 368 371
36. K.O. Boman, J.H. Jansson, K.A. Nyhlen, and T.K. Nilsson Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction Thromb. Haemost. 87 2002 311 316
37. G.P. Jones Spironolactone and risk of upper gastrointestinal events: causality remains unconvincing BMJ 333 2006 501